Abstract:Background and Aims: The low cancer specificity of serum Prostate-Specific Antigen (PSA), the principal biomarker for prostate cancer detection, leads to a high frequency of unwarranted prostate biopsies. To alleviate this deficit, we executed a proteomic discovery study seeking PSA reflex signatures using the ProteographTM Product Suite, a multi-nanoparticle-based deep plasma/serum proteomics workflow (Seer, Inc.), with timsTOF Pro mass spectrometry (Bruker) to interrogate over 900 serum specimens from patients that underwent prostate biopsy due to elevated PSA and/or abnormal digital rectal exam. Methods: Our study followed rigorous design principles including uniform collection, randomization and blinding of specimens, all of which were processed with the Proteograph Product Suite. Liquid chromatography-mass spectrometry (LC-MS) analyses leveraged the Bruker timsTOF Pro MS platform utilizing 30-minute reversed-phase chromatography and a label-free dia-PASEF (data independent acquisition - parallel accumulation serial fragmentation) data acquisition method. Peptides deriving from a chosen subset of specimens designed to maximize peptide diversity were pooled, fractionated and analyzed using DDA (data-dependent acquisition)-PASEF to build a spectral reference library. Results: The DIA-NN algorithm was employed through the cloud-based Proteograph Analysis Suite (PAS) to search LC-MS data. Leveraging our study-specific spectral library proteomic depth achieved was approximately 3600 protein groups identified (median) per patient serum specimen and more than 4400 in at least 25% of samples across the study. Customized machine learning workflows and the SeerML pipeline were used to identify and assess diagnostic power of new proteomic signatures. Conclusions: Our data demonstrate the remarkable proteomic depth achievable in a scaled patient serum specimen discovery study using a combination of Proteograph and timsTOF platforms. This significant effort revealed serum proteomic signatures with increased diagnostic performance over that provided by PSA blood measurement and traditional patient-associated metadata alone, providing a foundation for future clinical tests aimed to reduce the current high frequency of unnecessary prostate biopsy. Citation Format: Mark Flory, Matthew Chang, Jessie May Cartier, Jane Lange, Travis Moore, James McGann, Ryan Kopp, Michael Liss, Robin Leach, Brenna Albracht, James Dai, Michael Krawitzky, Eltaher Elgierari, Jessica Chu, Paul Pease, Max Mahoney, Shadi Ferdosi, Ryan Benz, Khatereh Motamedchaboki, Asim Siddiqui, Mahdi Zamanighomi, Amir Alavi, Harendra Guturu, Daniel Hornburg, Serafim Batzoglou. A scaled proteomic discovery study for prostate cancer diagnostic signatures using Proteograph workflow with trapped ion mobility mass spectrometry [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7090.

A prostate cancer tissue specific spectral library for targeted proteomic analysis

The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis.

Abstract P326: an Innovative Peptide Spectral Library Search Engine for Cardiovascular Proteomics

High‐throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification

Discovery and Multi-center Verification of Prostate Cancer Protein Biomarkers using Single-shot Short Gradient Microflow SWATH and MRMHR Mass Spectrometry

DPHL:A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery

Prostate Carcinoma Tissue Proteomics for Biomarker Discovery.

DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery

3-D tissue typing of prostate tissue based on spectral parameters

DPHL: A pan human protein mass spectrometry library for robust biomarker discovery using Data Independent Acquisition and Parallel Reaction Monitoring

Evaluation of Prostate Cancer Based on MALDI-TOF MS Fingerprinting of Nanoparticle-Treated Serum Proteins/peptides.

Abstract LB-063: A High-Resolution, Quantitative Proteomic Map of Human Prostate Cancer Cells

Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction

Accelerated Protein Biomarker Discovery from FFPE Tissue Samples Using Single-Shot, Short Gradient Microflow SWATH MS

iTRAQ technology combined 2DLC-MS/MS differentially expressed proteins in prostate cancer screening

Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry

Relative Protein Quantification and Accessible Biology in Lung Tumor Proteomes from Four LC-MS/MS Discovery Platforms

A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using ProteographTM and Trapped Ion Mobility Mass Spectrometry

Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment

Proteomics in prostate cancer biomarker discovery

Abstract 7090: A scaled proteomic discovery study for prostate cancer diagnostic signatures using Proteograph workflow with trapped ion mobility mass spectrometry